Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic concepts and biological pathways without new human empirical data or systematic search methods.
PubMed 29757195 · doi:10.1172/JCI97943
What was done
This narrative review synthesizes the biological mechanisms governing the active resolution of acute inflammation. It outlines the biosynthesis and actions of specialized pro-resolving mediator (SPM) families—including resolvins, protectins, and maresins—and describes their roles in immune regulation and potential therapeutic applications.
What was found
The abstract reports no numerical data, effect estimates, or statistical findings. It conceptually describes resolvins, protectins, and maresins as bioactive metabolomes that limit innate immune responses, enhance microbial killing and clearance, and protect tissues from collateral damage.
Why it matters
It highlights that resolving inflammation is an active, biochemically controlled process rather than passive decay, proposing immunoresolvent therapies as non-immunosuppressive alternatives for inflammatory diseases.
Limits
The abstract describes a narrative overview rather than a systematic review or empirical clinical trial. No original experimental data, sample sizes, patient populations, or comparative efficacy measures are provided.
Cited by
- supports Charles Serhan at Harvard demonstrated that specialized pro-resolving mediators like resolvins and maresins derived from omega-3 fatty acids are critical for resolving inflammation.